PTCT241220P38000
- 4.20
- 0.000.00%
PTC Therapeutics Newsroom
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $62
Express News | PTC Therapeutics Inc : JP Morgan Raises Target Price to $62 From $51
Sector Update: Health Care Stocks Advance Pre-Bell Thursday
PTC Therapeutics Is Maintained at Equal-Weight by Barclays
PTC Therapeutics Analyst Ratings
Sector Update: Health Care
Express News | FDA- FDA Granted Approval of Kebilidi to PTC Therapeutics, Inc
Top Premarket Gainers
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $45
ClearPoint Neuro Says FDA Granted Marketing Authorization for SmartFlow Neuro Cannula
Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)
PTC Therapeutics Gains Buy Rating Following FDA Approval of Groundbreaking Gene Therapy Kebilidi
PTC Therapeutics' AADC Deficiency Gene Therapy Granted FDA Approval
Express News | PTC Therapeutics Inc - Priority Review Voucher Granted
Express News | PTC Therapeutics Announces FDA Approval of Aadc Deficiency Gene Therapy
Balancing Growth Prospects and Regulatory Challenges: A Hold Rating on PTC Therapeutics
PTC Therapeutics (PTCT) Receives a Hold From Barclays
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $45 to $48
JFrog Slips as Earnings Season Hops Along While Pair of Semis Rebound
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $48